Show simple item record

dc.contributor.authorZafeiriou, Z
dc.contributor.authorBianchini, D
dc.contributor.authorChandler, R
dc.contributor.authorRescigno, P
dc.contributor.authorYuan, W
dc.contributor.authorCarreira, S
dc.contributor.authorBarrero, M
dc.contributor.authorPetremolo, A
dc.contributor.authorMiranda, S
dc.contributor.authorRiisnaes, R
dc.contributor.authorRodrigues, DN
dc.contributor.authorGurel, B
dc.contributor.authorSumanasuriya, S
dc.contributor.authorPaschalis, A
dc.contributor.authorSharp, A
dc.contributor.authorMateo, J
dc.contributor.authorTunariu, N
dc.contributor.authorChinnaiyan, AM
dc.contributor.authorPritchard, CC
dc.contributor.authorKelly, K
dc.contributor.authorde Bono, JS
dc.date.accessioned2019-04-24T08:40:46Z
dc.date.issued2019-01
dc.identifier.citationEuropean urology, 2019, 75 (1), pp. 184 - 192
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3201
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2018.09.048
dc.description.abstractPlatinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
dc.formatPrint-Electronic
dc.format.extent184 - 192
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectAdenocarcinoma
dc.subjectCarboplatin
dc.subjectAntineoplastic Agents
dc.subjectPedigree
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectDNA Repair-Deficiency Disorders
dc.subjectRecombinational DNA Repair
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleGenomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
dc.typeJournal Article
dcterms.dateAccepted2018-09-27
rioxxterms.versionofrecord10.1016/j.eururo.2018.09.048
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2019-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Translational Therapeutics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume75
pubs.embargo.termsNot known
icr.researchteamCancer Biomarkersen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTranslational Therapeuticsen_US
dc.contributor.icrauthorSumanasuriya, Seminien
dc.contributor.icrauthorGurel, Boraen
dc.contributor.icrauthorRescigno, Pasqualeen
dc.contributor.icrauthorSharp, Adamen
dc.contributor.icrauthorCarreira, Suzanneen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorMateo Valderrama, Joaquinen
dc.contributor.icrauthorMiranda, Susanaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0